Published in
Springer (part of Springer Nature), Targeted Oncology, 3(11), p. 401-415
DOI: 10.1007/s11523-016-0435-8
Links
Tools
An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib.
Journal article published in 2016 by
J. Mateo,
V. Moreno 
,
A. Gupta,
S. B. Kaye,
Emma J. Dean ,
M. R. Middleton,
M. Friedlander,
C. Gourley,
R. Plummer,
G. Rustin,
C. Sessa,
K. Leunen,
J. Ledermann,
H. Swaisland,
A. Fielding
and other authors.
,
A. Gupta,
S. B. Kaye,
Emma J. Dean ,
M. R. Middleton,
M. Friedlander,
C. Gourley,
R. Plummer,
G. Rustin,
C. Sessa,
K. Leunen,
J. Ledermann,
H. Swaisland,
A. Fielding
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Olaparib is poorly soluble, requiring advanced drug delivery technologies for adequate bioavailability. Sixteen capsules/day are required for the approved 400 mg twice-daily dose; a tablet formulation was developed to reduce pill burden. This clinical trial evaluated the optimal dose and administration schedule of the tablet formulation.